Skip to main content
Erschienen in: Tumor Biology 7/2016

16.01.2016 | Original Article

SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer

verfasst von: Yongchun Song, Jianli Zhang, Tao Tian, Xiao Fu, Wenjuan Wang, Suoni Li, Tingting Shi, Aili Suo, Zhiping Ruan, Hui Guo, Yu Yao

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

SET7/9 is a protein lysine methyltransferase that had been initially identified as a histone lysine methyltransferase which generates monomethylation at histone 3 lysine 4. Different functions were attributed to the protein methylation mediated by SET7/9. In this study, we found that the expression of SET7/9 declined in a majority of the human breast cancer tissues examined compared with normal tissues. Knockdown of SET7/9 promoted the proliferation, migration, and invasion of breast cancer cells. Knockdown of SET7/9 also increased the tumorigenicity of breast cancer cells in vivo. On the contrary, overexpression of SET7/9 in breast cancer cells inhibited these processes. Microarray analysis indicated that Gli-1 may play function as a downstream factor of SET7/9. Overexpression of SET7/9SET7/9 inhibits Gli-1 expression. While knockdown of SET7/9 promotes the expression of Gli-1. Gli-1 inhibited by cyclopamine blocked knockdown SET7/9-driven proliferation, migration, and invasion in breast cancer cell. Furthermore, Gli-1 expression in human breast cancer tissues is negatively correlated with SET7/9 expression. Together, these results helped to realize the antioncogene functions of SET7/9 in breast cancer cells and provided a novel direction to treat breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMed DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMed
2.
Zurück zum Zitat Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.CrossRefPubMed Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.CrossRefPubMed
3.
Zurück zum Zitat Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X, et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules. 2013;19(1):159–76.CrossRefPubMed Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X, et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules. 2013;19(1):159–76.CrossRefPubMed
4.
Zurück zum Zitat Zhang X, Bruice TC. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. Proc Natl Acad Sci U S A. 2008;105(15):5728–32.CrossRefPubMedPubMedCentral Zhang X, Bruice TC. Enzymatic mechanism and product specificity of SET-domain protein lysine methyltransferases. Proc Natl Acad Sci U S A. 2008;105(15):5728–32.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hu P, Wang S, Zhang Y. How do SET-domain protein lysine methyltransferases achieve the methylation state specificity? Revisited by Ab initio QM/MM molecular dynamics simulations. J Am Chem Soc. 2008;130(12):3806–13.CrossRefPubMedPubMedCentral Hu P, Wang S, Zhang Y. How do SET-domain protein lysine methyltransferases achieve the methylation state specificity? Revisited by Ab initio QM/MM molecular dynamics simulations. J Am Chem Soc. 2008;130(12):3806–13.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002;111(1):105–15.CrossRefPubMed Wilson JR, Jing C, Walker PA, Martin SR, Howell SA, Blackburn GM, et al. Crystal structure and functional analysis of the histone methyltransferase SET7/9. Cell. 2002;111(1):105–15.CrossRefPubMed
7.
Zurück zum Zitat Couture JF, Collazo E, Hauk G, Trievel RC. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 2006;13(2):140–6.CrossRefPubMed Couture JF, Collazo E, Hauk G, Trievel RC. Structural basis for the methylation site specificity of SET7/9. Nat Struct Mol Biol. 2006;13(2):140–6.CrossRefPubMed
8.
Zurück zum Zitat Kwon T, Chang JH, Kwak E, Lee CW, Joachimiak A, Kim YC, et al. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J. 2003;22(2):292–303.CrossRefPubMedPubMedCentral Kwon T, Chang JH, Kwak E, Lee CW, Joachimiak A, Kim YC, et al. Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. EMBO J. 2003;22(2):292–303.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, et al. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003;421(6923):652–6.CrossRefPubMed Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, et al. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003;421(6923):652–6.CrossRefPubMed
10.
Zurück zum Zitat Liu M, Zhang W, Tang W, Wang Y, Zhao X, Wang X et al. Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biol. 2015. Epub. Liu M, Zhang W, Tang W, Wang Y, Zhao X, Wang X et al. Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells. Tumour Biol. 2015. Epub.
11.
Zurück zum Zitat Fujimaki K, Ogihara T, Morris DL, Oda H, Iida H, Fujitani Y, et al. SET7/9 enzyme regulates cytokine-induced expression of inducible nitric-oxide synthase through methylation of lysine 4 at histone 3 in the islet beta cell. J Biol Chem. 2015;290(27):16607–18.CrossRefPubMedPubMedCentral Fujimaki K, Ogihara T, Morris DL, Oda H, Iida H, Fujitani Y, et al. SET7/9 enzyme regulates cytokine-induced expression of inducible nitric-oxide synthase through methylation of lysine 4 at histone 3 in the islet beta cell. J Biol Chem. 2015;290(27):16607–18.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, et al. KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget. 2015;6(28):25843–55.CrossRefPubMedPubMedCentral Lezina L, Aksenova V, Fedorova O, Malikova D, Shuvalov O, Antonov AV, et al. KMT Set7/9 affects genotoxic stress response via the Mdm2 axis. Oncotarget. 2015;6(28):25843–55.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat He S, Owen DR, Jelinsky SA, Lin LL. Lysine methyltransferase SETD7 (SET7/9) regulates ROS signaling through mitochondria and NFE2L2/ARE pathway. Sci Rep. 2015;5:14368.CrossRefPubMedPubMedCentral He S, Owen DR, Jelinsky SA, Lin LL. Lysine methyltransferase SETD7 (SET7/9) regulates ROS signaling through mitochondria and NFE2L2/ARE pathway. Sci Rep. 2015;5:14368.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene. 2010;29(16):2357–67.CrossRefPubMed Munro S, Khaire N, Inche A, Carr S, La Thangue NB. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene. 2010;29(16):2357–67.CrossRefPubMed
15.
Zurück zum Zitat Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, et al. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol Cell. 2011;43(4):681–8.CrossRefPubMed Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, et al. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Mol Cell. 2011;43(4):681–8.CrossRefPubMed
16.
Zurück zum Zitat Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell. 2008;29(3):392–400.CrossRefPubMed Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell. 2008;29(3):392–400.CrossRefPubMed
17.
Zurück zum Zitat Macaron NC, Cohen C, Chen SC, Arbiser JL. gli-1 Oncogene is highly expressed in granulomatous skin disorders, including sarcoidosis, granuloma annulare, and necrobiosis lipoidica diabeticorum. Arch Dermatol. 2005;141(2):259–62.CrossRefPubMed Macaron NC, Cohen C, Chen SC, Arbiser JL. gli-1 Oncogene is highly expressed in granulomatous skin disorders, including sarcoidosis, granuloma annulare, and necrobiosis lipoidica diabeticorum. Arch Dermatol. 2005;141(2):259–62.CrossRefPubMed
18.
Zurück zum Zitat Sananto D, Noer S, Alsagaff JH. Gli-1 oncogene: the key to keloidogenesis? Plast Reconstr Surg. 2007;119(3):1146–7.CrossRefPubMed Sananto D, Noer S, Alsagaff JH. Gli-1 oncogene: the key to keloidogenesis? Plast Reconstr Surg. 2007;119(3):1146–7.CrossRefPubMed
19.
Zurück zum Zitat ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. 2009;9:298.CrossRefPubMedPubMedCentral ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. 2009;9:298.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Lei J, Fan L, Wei G, Chen X, Duan W, Xu Q, et al. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol. 2015;36(4):3119–26.CrossRefPubMed Lei J, Fan L, Wei G, Chen X, Duan W, Xu Q, et al. Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer. Tumour Biol. 2015;36(4):3119–26.CrossRefPubMed
21.
Zurück zum Zitat Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG, Jin YB, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol. 2014;35(2):1357–63.CrossRefPubMed Wang ZS, Shen Y, Li X, Zhou CZ, Wen YG, Jin YB, et al. Significance and prognostic value of Gli-1 and Snail/E-cadherin expression in progressive gastric cancer. Tumour Biol. 2014;35(2):1357–63.CrossRefPubMed
Metadaten
Titel
SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer
verfasst von
Yongchun Song
Jianli Zhang
Tao Tian
Xiao Fu
Wenjuan Wang
Suoni Li
Tingting Shi
Aili Suo
Zhiping Ruan
Hui Guo
Yu Yao
Publikationsdatum
16.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4822-7

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.